Evidence map›Paper›PMID 38318230›Full record

ArticleVaccine: X2024

Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States.

J Bradley Layton, Lauren Peetluk, Hui Lee Wong, Yixin Jiao, Djeneba Audrey Djibo, Christine Bui, Patricia C Lloyd, Joann F Gruber, Michael Miller, Rachel P Ogilvie and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

J Bradley LaytonRTI Health Solutions, Research Triangle Park, NC, USA.
Lauren PeetlukOptum Epidemiology, Boston, MA, USA.
Hui Lee WongUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Yixin JiaoAcumen, LLC, Burlingame, CA, USA.
Djeneba Audrey DjiboSafety, Surveillance & Collaboration, CVS Health, Blue Bell, PA, USA.
Christine BuiRTI Health Solutions, Research Triangle Park, NC, USA.
Patricia C LloydUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Joann F GruberUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Michael MillerOptum Epidemiology, Boston, MA, USA.
Rachel P OgilvieOptum Epidemiology, Boston, MA, USA.
Jie DengOptum Epidemiology, Boston, MA, USA.
Ron ParambiOptum Epidemiology, Boston, MA, USA.
Jennifer SongOptum Epidemiology, Boston, MA, USA.
Lisa B WeatherbyOptum Epidemiology, Boston, MA, USA.
An-Chi LoAcumen, LLC, Burlingame, CA, USA.
Kathryn MatuskaAcumen, LLC, Burlingame, CA, USA.
Michael WerneckeAcumen, LLC, Burlingame, CA, USA.
Tainya C ClarkeUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Sylvia ChoUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Elizabeth J BellOptum Epidemiology, Boston, MA, USA.
John D SeegerOptum Epidemiology, Boston, MA, USA.
Grace Wenya YangOptum Serve, Falls Church VA, USA.
Dóra IlleiRTI International, Washington, DC, USA.
Richard A ForsheeUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Steven A AndersonUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.
Cheryl N McMahill-WalravenSafety, Surveillance & Collaboration, CVS Health, Blue Bell, PA, USA.
Yoganand ChillarigeAcumen, LLC, Burlingame, CA, USA.
Kandace L AmendOptum Epidemiology, Boston, MA, USA.
Mary S AnthonyRTI Health Solutions, Research Triangle Park, NC, USA.
Azadeh ShoaibiUS Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of COVID-19 vaccine compared with receiving a primary vaccine series without a booster/additional dose. Methods: Cohorts of individuals receiving a COVID-19 booster/additional dose after receipt of a complete primary vaccine series were identified in 2 administrative insurance claims databases (Optum, CVS Health) supplemented with state immunization information system data between August 2021 and March 2022. Individuals with a complete primary series but without a booster/additional dose were one-to-one matched to boosted individuals on calendar date, geography, and clinical factors. COVID-19 diagnoses were identified in any medical setting, or specifically in hospitals/emergency departments (EDs). Propensity score-weighted hazards ratios (HRs) and 95% confidence intervals (CI) were estimated with Cox proportional hazards models; vaccine effectiveness (VE) was estimated as 1 minus the HR by vaccine brand overall and within subgroups of variant-specific eras, immunocompromised status, and homologous/heterologous booster status. Results: Across both data sources, we identified 752,165 matched pairs for BNT162b2, 410,501 for mRNA-1273, and 11,398 for JNJ-7836735. For any medically diagnosed COVID-19, meta-analyzed VE estimates for BNT162b2, mRNA-1273, and JNJ-7836735, respectively, were: BNT162b2, 54% (95% CI, 53%-56%); mRNA-1273, 58% (95% CI, 56%-59%); JNJ-7836735, 34% (95% CI, 23%-44%). For hospital/ED-diagnosed COVID-19, VE estimates ranged from 70% to 76%. VE was generally lower during the Omicron era than the Delta era and for immunocompromised individuals. There was little difference observed by homologous or heterologous booster status. Conclusion: The original, monovalent booster/additional doses were reasonably effective in real-world use among the populations for which they were indicated during the study period. Additional studies may be informative in the future as new variants emerge and new vaccines become available.Registration: The study protocol was publicly posted on the BEST Initiative website (https://bestinitiative.org/wp-content/uploads/2022/03/C19-VX-Effectiveness-Protocol_2022_508.pdf).

Indexed as

COVID-19 vaccinesPharmacoepidemiologyVaccine effectiveness

Identifiers

PMID38318230
PMCPMC10840109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.